15
AASM Membership Sections Newsletter
�
Issue #7
American Academy of
Sleep Medicine
PETER BERNAD, MD
Dr. Peter Bernad, MD, is the founder
of Neurology Services, Inc. located
in Washington, DC. He attended
medical school at McGill University
in Montreal, Quebec, Canada and
continued on to receive his MPH
from John Hopkins University
in Baltimore, MD. He is a full
professor at George Washington
University School of Medicine and
Health Sciences in Washington,
DC. He’s won multiple awards and
is associated with the American
Academy of Sleep Medicine (AASM),
American Board of Internal Medicine
(ABIM), American Board of Psychiatry
and Neurology (ABPN) and the EEG
and Clinical Neuroscience Society
(ECNS). This is his first year serving
on the Narcolepsy Section Steering
Committee.
ROSEMARIE ROHATGI, DMD
Dr. Rosemarie Rohatgi, DMD, is
President of San Diego Sleep Therapy
in San Diego, CA and has been
practicing medicine for 17 years. She
dedicates her entire practice to dental
sleep medicine and was recognized
in 2013 by San Diego Magazine
as one of the city’s leading woman
Entrepreneurs. Dr. Rohatgi attended
the University of Oregon on a full
academic scholarship and graduated
with honors in Chemistry. She
received her Doctorate in Medical
Dentistry from Oregon Health
Sciences University with honors
in Endodontics and Removable
Prosthodontics. An active member
of the AASM and the AADSM, Dr.
Rohatgi is serving her first year on
the Narcolepsy Section Steering
Committee after having previously
served on the American Student
Dental Association as a consultant
on National Dental Examinations and
on the American Dental Association
as Commissioner on National Dental
Examinations. Dr. Rohatgi has
been nominated for the past two
consecutive years as “Woman of the
Year” by San Diego Magazine and
is also a member of the California
Sleep Society, the Academy of
General Dentistry, the American
Dental Association, the California
Dental Association and the San Diego
County Dental Society.
�
they are utilized at the common clinical level of care. Multi-center studies with proper
design are indicated. Public health and welfare issues, plus risk factors, weigh in.
Insomnia is a serious medical and social problem. Prevalence ranges up to 35% of pop-
ulations. The lost annual national productivity due to insomnia is suggested to be over
$63 billion dollars. Patients are subject to inappropriate and dangerous pharmacother-
apies. Many current modalities aimed at management of insomnia fall short. However,
given the relative paucity of bench research and clinical data regarding the newly un-
covered OXR antagonists and the gravity of the potential adverse events – as disclosed
– this raises the obligation to stay the hand of industry while further investigative facts,
regarding safety and efficacy, are ascertained. Any narcolepsy section members who
would like additional information on our topic of interest consider attending “BO1”
entitled “The Orexins: Bench to Bedside and Beyond.”
REFERENCES:
1.
Citrome L. Suvorexant for insomnia: a systematic review of the efficacy
and safety profile for this newly approved hypnotic. Int J Clin Prac 2014
Dec;68(12):1429-41. doi: 10.1111/ijcp. 12568.
2.
Herring WF, Conner KM, Ivgy-May…Michelson D. Suvorexant in Patients
with Insomnia: Results from Two 3-month randomized Controlled clinical trials.
Biol Psychiatry. 2014 Oct 23. Pii. S0006-3223(14)00762-8. doi: 10.1016/j.
biopsych.2014.10.003.
3.
Mould R, Brown J, Marshall FH, Langmead CJ. Binding kinetics differentiates
functional antagonism of orexin-2 receptor ligands. Br J Pharmacol. 2014
Jan;171(2):351-63. doi: 10/1111/bph. 12245.
4.
Merkle FT, Maroof A,…Schier AF. Generation of neuropeptidergic
hypothalamic neurons from human pluripotent stem cells. Development 2015
Feb 15;142(4):633-43. doi: 10.1242/dev.117978
5.
Morairty SR, Revel FG, …Boroni E. Dual hypocretin receptor antagonism is
more effective for sleep promotion than antagonism of either receptor alone.
PLoS One. 2012;7(7):e39131. doi: 10.1371/journal.pone.0039131
6.
Palasz A, Lapray D…Wiaderkiewicz R. Dual orexin receptor antagonists
– promising agents in the treatment of sleep disorders. Int J
Neuropsychopharmacol. 2014 Jan;17(1):157-68. doi: 10.
7.
Patel KV, Aspesi AV, Evoy KE. Suvorexant: A Dual Orexin Receptor Antagonist
for the Treatment of Sleep Onset and Sleep Maintenance Insomnia. Ann
Pharmacother. 2015 Feb 9. pii: 1060028015570467.
8.
Sullivan S. Update on emerging drugs for insomnia. Expert Opin Emerg Drugs.
2012 Sep;17(3):295-8. doi: 10. 151714728214.2012.693158.
9.
Sun H, Kennedy WP…Murphy GM. Effects of suvorexant, an orexin receptor
antagonist, on sleep parameters as measured by polysomnography in healthy
men. Sleep 2013 Feb 1;36(2):259-67. doi: 10.5665/sleep.2386.
